Testing and treatment identification occur within WCG Precision Therapy through CytoVantage 3D. CTI Biopharma advances selected combinations into defined therapies and clinical development.
CTI Biopharma translates selected combinations into defined therapies, generates clinical evidence, and advances those therapies toward regulatory approval and use.
Design and execute clinical trials for selected three-drug therapies.
Build the clinical data needed to validate response and support development.
Advance therapies toward approval and commercial use.
CT30x represents therapies developed from observed tumor response. CT301 is the first therapy in this series and is currently in clinical trials. Additional therapies will follow as new combinations are identified.
Testing and treatment identification occur within WCG through CytoVantage 3D, where a broad range of therapies and combinations are evaluated.
CTI therapies are included in evaluation, but they are not predetermined outcomes.
CTI Biopharma develops therapies where strong and repeatable activity is demonstrated.